356 related articles for article (PubMed ID: 30138772)
41. Immunoactive treatment for myasthenia gravis; a Chinese experience.
Gilhus NE
CNS Neurosci Ther; 2020 Dec; 26(12):1203-1204. PubMed ID: 33107208
[No Abstract] [Full Text] [Related]
42. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
43. Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma.
Wang J; Wu X; Deng H; Liu Y; Liu H; Fan X; Liu K; Wu J; Zhang HL
Neurosciences (Riyadh); 2016 Jan; 21(1):77-8. PubMed ID: 26818174
[No Abstract] [Full Text] [Related]
44. Generalized morphea in the setting of pembrolizumab.
Cheng MW; Hisaw LD; Bernet L
Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
[No Abstract] [Full Text] [Related]
45. [Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases].
Reyes-Bueno JA; Rodriguez-Santos L; Serrano-Castro PJ
Rev Neurol; 2019 Apr; 68(8):333-338. PubMed ID: 30963530
[TBL] [Abstract][Full Text] [Related]
46. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
Li H; Huang Z; Jia D; Xue H; Pan J; Zhang M; Shi K; Shi FD; Zhang C
J Neuroimmunol; 2021 May; 354():577528. PubMed ID: 33662696
[TBL] [Abstract][Full Text] [Related]
47. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma.
Denny J; Chong H; Akhras V
Clin Exp Dermatol; 2018 Apr; 43(3):354-356. PubMed ID: 29222829
[No Abstract] [Full Text] [Related]
48. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H
Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202
[TBL] [Abstract][Full Text] [Related]
49. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab.
Chan F; Swayne A; Gillis D; Walsh M; Henderson RD; McCombe PA; Wong RC; Blum S
J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):955-956. PubMed ID: 30455407
[No Abstract] [Full Text] [Related]
50. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
Woodbeck R; Metelitsa AI; Naert KA
Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
[TBL] [Abstract][Full Text] [Related]
51. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
Fiset PO; Shapera S; Butler MO; Tsao MS
Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
[No Abstract] [Full Text] [Related]
52. Multiple "halo nevi" occurring during pembrolizumab treatment for metastatic melanoma.
Nicolétis-Lombart I; Kervarrec T; Zaragoza J; Machet MC; Samimi M
Int J Dermatol; 2019 Jun; 58(6):739-741. PubMed ID: 30229873
[No Abstract] [Full Text] [Related]
53. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
[No Abstract] [Full Text] [Related]
54. Myasthenia gravis induced by pembrolizumab in a patient with metastatic Merkel cell carcinoma.
Pottier C; El Habnouni C; Kervarrec T; Beltran S; Samimi M
Ann Dermatol Venereol; 2022 Jun; 149(2):142-145. PubMed ID: 35190214
[No Abstract] [Full Text] [Related]
55. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
[TBL] [Abstract][Full Text] [Related]
56. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
Durães J; Coutinho I; Mariano A; Geraldo A; Macário MC
Mult Scler; 2019 Jun; 25(7):1005-1008. PubMed ID: 30311534
[TBL] [Abstract][Full Text] [Related]
57. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
[No Abstract] [Full Text] [Related]
58. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid.
Ridpath AV; Rzepka PV; Shearer SM; Scrape SR; Olencki TE; Kaffenberger BH
Int J Dermatol; 2018 Nov; 57(11):1372-1374. PubMed ID: 29624655
[No Abstract] [Full Text] [Related]
59. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
60. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
